Overview

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

The primary objective of this trial is to evaluate the safety and efficacy of two doses of tiotropium inhalation solution delivered via the Respimat® inhaler once daily in the afternoon in patients (1 to 5 years old) with persistent asthma on top of inhaled corticosteroid (ICS) treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Boehringer Ingelheim

Collaborator:

Pfizer

Treatments:

Bromides
Tiotropium Bromide